QELBREE
- Product NDC
- 17772-131
- 11-digit product format
- 177720131
- Labeler code
- 17772
- Product ID
- 17772-131_453c9f61-1902-44ab-e063-6394a90ab639
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- viloxazine hydrochloride
- Dosage form
- CAPSULE, EXTENDED RELEASE
- Route
- ORAL
- Labeler
- Supernus Pharmaceuticals, Inc
- Application
- NDA211964
- Marketing category
- NDA
- Marketing start
- 2021-04-02
- Substance
- VILOXAZINE HYDROCHLORIDE
- Active strength
- 100 mg/1
- Pharmacologic classes
- Cytochrome P450 1A2 Inhibitors [MoA], Cytochrome P450 2B6 Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Norepinephrine Reuptake Inhibitor [EPC], Norepinephrine Uptake Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- QELBREE
- Listing expiration
- 2026-12-31
Active Ingredients#
Ingredient, Strength table| Ingredient | Strength |
|---|
| VILOXAZINE HYDROCHLORIDE | 100 mg/1 |
Harmonized Identifiers#
Field, Values table| Field | Values |
|---|
| Unii | OQW30I1332 |
| Rxcui | 2536548, 2536554, 2536750, 2536752, 2536756, 2536758 |
DailyMed Product Concepts#
DailyMed Package Descriptions#
Package NDC, Product, Description table| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|
| 17772-131-01 | QELBREE | 100 in 1 BOTTLE | CAPSULE, EXTENDED RELEASE | 100 | | 14 |
| 17772-131-07 | QELBREE | 7 in 1 BOTTLE | CAPSULE, EXTENDED RELEASE | 7 | | 14 |
| 17772-131-30 | QELBREE | 30 in 1 BOTTLE | CAPSULE, EXTENDED RELEASE | 30 | | 14 |
| 17772-131-60 | QELBREE | 60 in 1 BOTTLE | CAPSULE, EXTENDED RELEASE | 60 | | 14 |
| 17772-131-90 | QELBREE | 90 in 1 BOTTLE | CAPSULE, EXTENDED RELEASE | 90 | | 14 |
DailyMed Dashboard NDC Coverage#
NDC, Dashboard title, SPL version table| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|
| 17772-131 | QELBREE (VILOXAZINE HYDROCHLORIDE) CAPSULE, EXTENDED RELEASE [SUPERNUS PHARMACEUTICALS, INC] | 10 | Current NDC, Legacy NDC, 5 package rows | 20250202_aedf408d-0f84-418d-9416-7c39ddb0d29a.zip |
DailyMed RxNorm Mappings#
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 17772-131-01 | 17772013101 | 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-131-01) | 2021-04-02 | 0000-00-00 | No | No | Current |
| 17772-131-07 | 17772013107 | 7 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-131-07) | 2021-04-02 | 0000-00-00 | Yes | No | Current |
| 17772-131-30 | 17772013130 | 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-131-30) | 2021-04-02 | 0000-00-00 | No | No | Current |
| 17772-131-60 | 17772013160 | 60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-131-60) | 2021-04-02 | 0000-00-00 | No | No | Current |
| 17772-131-90 | 17772013190 | 90 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-131-90) | 2021-04-02 | 0000-00-00 | No | No | Current |